Neural Regeneration Research ›› 2015, Vol. 10 ›› Issue (8): 1181-1185.doi: 10.4103/1673-5374.162686

    Next Articles

Curcumin and Apigenin – novel and promising therapeutics against chronic neuroinflammation in Alzheimer’s disease

Madhuri Venigalla1, Erika Gyengesi1, 3, Gerald Münch1, 2, 3, *   

  1. 1 Department of Pharmacology, School of Medicine, University of Western Sydney, Campbelltown, NSW, Australia
    2 National Institute of Complementary Medicine, University of Western Sydney, Penrith, NSW, Australia
    3 Molecular Medicine Research Group, University of Western Sydney, Penrith, NSW, Australia
  • Received:2015-05-21 Online:2015-08-24 Published:2015-08-24
  • Contact: Gerald Münch, Ph.D., g.muench@uws.edu.au.

PDF

618

Abstract:

Alzheimer’s disease is a progressive neurodegenerative disorder, characterized by deposition of amyloid beta, neurofibrillary tangles, astrogliosis and microgliosis, leading to neuronal dysfunction and loss in the brain. Current treatments for Alzheimer’s disease primarily focus on enhancement of cholinergic transmission. However, these treatments are only symptomatic, and no disease-modifying drug is available for Alzheimer’s disease patients. This review will provide an overview of the proven antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and cognition-enhancing effects of curcumin and apigenin and discuss the potential of these compounds for Alzheimer’s disease prevention and treatment. We suggest that these compounds might delay the onset of Alzheimer’s disease or slow down its progression, and they should enter clinical trials as soon as possible.

Key words: Alzheimer’s disease, neuroinflammation, anti-inflammatory drugs, plant secondary metabolites, reactive oxygen species